Relindis Tita
Psychiatry · Oklahoma City, OKNPI 1164155693
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 335 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- AbbVie$995
- Otsuka America Pharmaceutical, Inc.$761
- Axsome Therapeutics, Inc.$624
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$624
- Teva Pharmaceuticals USA, Inc.$423
- plus $2K from 16 others
What the payments were for
- Food & beverage$6,465100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$369
- CAPLYTA$231
- Auvelity$217
- QELBREE$146
- VRAYLAR$125
- REXULTI$122
- Austedo XR$116
How this compares
$6,465 in reported general payments places this provider in the 90th percentile of 328 psychiatry providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxcarbazepine | 11 | $1,093 |
| Mirtazapine | 12 | $195 |
| Sertraline Hcl | 15 | $108 |
| Hydroxyzine Hcl | 14 | $104 |
| Trazodone Hcl | 22 | $84 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $38 | $10815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Oklahoma City
- Willis HollowayOklahoma City$92K
- Adonis Al BotrosOklahoma City$73K
- Marvin PeytonOklahoma City$60K
- Josephine DeguzmanOklahoma City$38K
- Haisam Al KhouriOklahoma City$10K
- Patrick HornOklahoma City$8K
- Shreekuma VinekarOklahoma City$7K
- Janita ArdisOklahoma City$6K
- Fiona LiOklahoma City$5K
- Ahsan KhanOklahoma City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.